XBIT News and Press, XBiotech Inc. From 05/23/19

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidra...

XBiotech and Cedars-Sinai Medical Center Evaluate Bermekimab in Combination with Chemotherapy in Patients with Pancreatic Cancer and Cachexia AUSTIN, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today enrollment of the final patient into its Phase I study 1...

When you come out of the storm, you won’t be the same person who walked in. That’s what this storm’s all about. ” ― Haruki Murakami, Kafka on the Shore Today, we take a look at a name in the biotech sector that does not get much cover despite a sizable m...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model and comments are expressly based on his own proprietary methodology and forecasts. Winning Bounce/Lag Momentum Stocks for Week 12 of 2019 The Bounce/L...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model and comments are expressly based on his own proprietary methodology and forecasts. Winning Bounce/Lag Momentum Stocks For Week 11 of 2019 The Bounce/La...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

XBiotech (NASDAQ: XBIT ) is up  4%  premarket, albeit on only 600 shares, on the heels of positive results from a Phase 2 clinical trial evaluating bermekimab in patients with a chronic inflammatory skin disorder called hidradenitis suppurativa (HS), first reported in late Ja...

- Significant therapeutic benefit achieved whether or not patients had previously failed treatment with existing FDA-approved biological drug. - 61-63% of patients achieved a positive HiSCR (the accepted measure of disease severity in HS). -  67-72% of patients achieved a clinicall...

Thinly traded micro cap XBiotech ( XBIT +13.4% ) is up on over triple normal volume, albeit on turnover of only 484K shares, on the heels of positive results from a Phase 2 clinical trial evaluating bermekimab in patients with moderate-to-severe atopic dermatitis (AD). The data will be...

Rapid and significant reduction in skin lesions, 66% (p<0.001) and 76% (p<0.001) mean reduction in EASI score in 4 and 7 weeks, respectively.   Rapid and significant resolution of worst itch and pain, 57% (p<0.001) and 61% (p<0.001) mean reduction within 4 weeks, respecti...